Autopsy report · NCT03491150

An Open-Label Crenezumab Study in Participants With Alzheimer's Disease

“This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 2 months before it stopped.
• 149 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Hoffmann-La Roche

Sponsor type

Industry

Conditions

Alzheimer's Disease

Interventions

Crenezumab

Participants

149

Sites

66

Countries

Australia, Canada, Finland, France, Germany, Hong Kong, Italy, Lithuania, Mexico, Poland, Russia, South Korea and more

Trials that died the same way

• A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
  “This study was discontinued due to an interim analysis which indicated that ralmitaront was unlikely to meet its primary endpoint.” (62% match in meaning)
• Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.
  “B7911002 was prematurely discontinued due to a safety concern that led to decision to terminate the study on 10 Nov 2014” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.